Abstract
Erythropoiesis-stimulating agents (ESAs) are an option for the treatment of chemotherapy-induced anemia (CIA). The primary objective was to assess published cost-effectiveness analyses using ESAs as standard care (SC) for the treatment of CIA in non-myeloid cancer.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
